US Patent

US9918970 — Pharmaceutical composition comprising solifenacin

Formulation · Assigned to Astellas Pharma Inc · Expires 2031-05-18 · 5y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a pharmaceutical composition that combines solifenacin or a salt thereof with an ion exchange resin and an acrylic based polymer.

USPTO Abstract

Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer.

Drugs covered by this patent

solifenacin-succinate (SOLIFENACIN SUCCINATE)

Patent Metadata

Patent number: US9918970
Jurisdiction: US
Classification: Formulation
Expires: 2031-05-18
Drug substance claim: No
Drug product claim: Yes
Assignee: Astellas Pharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.